Webcast - Pharmaceutical/Biotech Accounting & Reporting Update Conference 2012

MAY 16, 2012

Chairman’s Welcome & Opening Remarks
8:45 – 9:00 AM

The Current Environment & Key Emerging Trends
9:00 – 10:15 AM
• Growth market and emerging opportunities
• Market and health care trends
• Scientific and technological trends
• In-house discovery vs. in-licensing and strategic alliances

Break
10:15 – 10:30 AM

Health Care Reform Update
10:30 AM – 12:00 PM
• New proposed rules for AMP and BP and the overall impact to the Medicaid Drug Program
• Potential impact on AMP calculation methodology and Medicaid rebate liabilities
• Emerging industry best practices to address the proposed rules
• Preparations that will be necessary to comply with proposed new rules
• Best practices for compliance
• Systems and procedural requirements
• Documentation and testing practices

Luncheon
12:00 – 12:45 PM

Regulatory Update: Aggregate Spend Reporting & the Sunshine Act
12:45 – 2:00 PM
• Update/status of the proposed changes to the Sunshine Act
• Issues within the Spend Reporting Compliance Continuum
• Aggregate spend disputes and inquiries from health care professionals

Break
2:00 – 2:15 PM

Valuation Considerations
2:15 – 3:45 PM
• M&A and intangible asset valuations
• Changes to the AICPA practice aid for IPR&D
• Alternative methodologies for IPR&D valuation
• Discount rate considerations
• Inventory valuation and complexities in the pharmaceutical industry
• Contingent consideration: accounting treatment and royalty arrangements
• Day Two impairment considerations and “Step 0”

Break
3:45 – 4:00 PM

Accounting for Debt Financing & Equity Transactions
4:00 – 5:00 PM
• In-depth analysis of accounting issues
• Equity derivatives
• Convertible securities
• Accounting for debt modifications

Cocktail Reception
5:00 – 6:00 PM

MAY 17, 2012

FASB & Technical Accounting Update: Roundtable Brief (Part I)
8:30 – 10:00 AM
• Revenue recognition and leases
• Collaborations, joint ventures and other alliances
• Current rules and new developments

Break
10:00 – 10:15 AM

FASB & Technical Accounting Update: Roundtable Brief (Part II)
10:15 AM – 12:00 PM
• Non-GAAP measures
• Loss contingencies
• Income taxes, including repatriation of earnings
• Impairments

Luncheon
12:00 – 1:00 PM

Deal-Making in the Industry
1:00 – 2:15 PM
• M&A activity: current trends and expectations in the industry
• M&A best practices
   – Initial interest and due diligence
   – Contract support
   – Closing and integration
• Key diligence areas of focus and value drivers: US vs. ex-US emerging markets

Break
2:15 – 2:30 PM

SEC Comment Letters
2:30 – 3:45 PM
• Key SEC staff messages
• Current issues impacting pharmaceutical companies
• Past areas of SEC staff focus
• Potential outcomes of a comment letter
• How does a review result in enforcement investigation?
• Best practices footnote disclosures
• Responding to the staff

Break
3:45 – 4:00 PM

Leadership in Pharmaceuticals & Biotechnology: Executive Roundtable
4:00 – 5:00 PM
• Life cycle management issues
• The impact of health care reform on the pharmaceutical and biotechnology industries
• Drug portfolio diversification
• Exclusivity losses
• Projecting pharmaceutical business trends in highly competitive markets

Conference Ends
5:00 PM